EN DE
STOCK COMPARISON

DNA Biomed Solns vs Marriott International: Fair Value & Quality

Both stocks run through our valuation models. Here is how DNA Biomed Solns (DNA) and Marriott International (MAR) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Marriott International as the less overvalued of the two: DNA Biomed Solns trades at ILS 0.99 versus a fair value of ILS 0.27 (-73%), while Marriott International trades at $354 versus $136 (-62%).
DNA Biomed Solns
DNA.TA · ILS · Information Technology
-73%
upside to fair value
overvalued
PriceILS 0.99
Fair ValueILS 0.27
Quality59/100
Marriott International
MAR · USD · Consumer Discretionary
-62%
upside to fair value
overvalued
Price$354
Fair Value$136
Quality69/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

DNA Biomed SolnsMarriott International
Valuation
P/E (TTM)38.0×
P/S (TTM)13.33×
2.97×P/B
EV/EBITDA23.3×
PEG2.16×
Dividend yield0.7%
Dividend per share$2.68
Profitability
169%Net margin36%
Operating margin59%
1%Return on equity14%
-1%Return on assets10%
Growth
0%Revenue growth (YoY)13%
Avg. growth/yr (3Y)8.0%
Avg. growth/yr (5Y)19.9%
Balance & size
0.18×Debt / equity
$301MMarket cap$96B
weakGrowth qualityhealthy

Marriott International leads: 1 to 3 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

DNA Biomed Solnsof which business quality 62 · market factors 42 Marriott Internationalof which business quality 63 · market factors 64
ProfitabilityMargins and returns on capital today
55
54
Quality GrowthAre margins and returns improving?
43
48
CashflowEarnings quality: real cash, not paper profit
75
56
Fin. StrengthBalance sheet, leverage, solvency risk
98
48
InvestmentDisciplined investing over empire-building
33
94
Low VolatilityCalm price path (market factor)
65
63
MomentumPrice trend over the last 3–12 months (market factor)
35
62
52W MomentumDistance to the 52-week high (market factor)
27
70
Net IssuanceBuybacks instead of dilution
40
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

DNA Biomed Solns

DCF ModelsILS 0.19
Earnings-BasedILS 0.24
MultiplesILS 0.38
Asset-BasedILS 0.08
Growth DCFILS 0.08
Economic ProfitILS 0.24
Growth EarningsILS 0.40

19 of 19 models see the stock below the current price.

Marriott International

DCF Models$128
Earnings-Based$73.56
Dividend Discount$46.38
Multiples$160
Growth DCF$98.20
Economic Profit$104
Growth Earnings$189

23 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

DNA Biomed Solns
Bear ILS 0.24Fair Value ILS 0.27Bull ILS 0.30
ILS 0.99 = current price (white tick)
Marriott International
Bear $69.84Fair Value $136Bull $206
$354 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

DNA Biomed Solns · Information Technology

Quality score59 · above median
Fair value upside-73% · bottom 25%

Marriott International · Consumer Discretionary

Quality score69 · Top 25%
Fair value upside-62% · bottom 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Marriott International as the less overvalued of the two: DNA Biomed Solns trades at ILS 0.99 versus a fair value of ILS 0.27 (-73%), while Marriott International trades at $354 versus $136 (-62%).

Marriott International has the higher quality score (69/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.